Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration?
- 15 April 2005
- journal article
- Published by Springer Science and Business Media LLC in Eye
- Vol. 20 (1), 43-45
- https://doi.org/10.1038/sj.eye.6701787
Abstract
Photodynamic therapy (PDT) is a new evidence-based treatment modality available for choroidal neovascularisation (CNV) secondary to age-related macular degeneratin (AMD). Eligibility for PDT is based on the morphological classification of the neovascular complex, the benefit being greater in classic with no occult lesions. Lesion size is also shown to be a predictive factor for treatment benefit. This retrospective case series looked at effect of initial and final lesion size on the visual outcome of patients with subfoveal classic with no occult CNV and found that increasing initial and final lesion size is associated with poorer visual outcome.Keywords
This publication has 6 references indexed in Scilit:
- Fluorescein angiographic lesion type frequency in neovascular Age-Related macular degenerationOphthalmology, 2004
- Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patternsAmerican Journal of Ophthalmology, 2004
- Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients With Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2002
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinAmerican Journal of Ophthalmology, 1999
- Ocular NeovascularizationSurvey of Ophthalmology, 1998